ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sonesitatug vedotin

Also written as “AZD0901”, “Sonesitatug Vedotin” and “Sonesitatug vedotin”.

Its studies are mostly in Stomach Neoplasms · Pancreatic Neoplasms, led by 2 companies.

Drug pageSonesitatug vedotin: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 28, 20247 company-led studies, 6 open or runningLicense: KYM Biosciences (Keymed and Lepu) → AstraZeneca, Feb 2023Next primary completion: Nov 9, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca66 open or runningphase 3since Feb 28, 2024Dec 7, 2022Nov 9, 2027phase 2 · NCT07069712
Keymed Biosciencesits history only10 open or runningphase 1since Mar 16, 2021Mar 16, 2021none ahead
  • Named in AstraZeneca’s own pipeline as sonesitatug vedotin, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 7, 2022First study: phase 2 study in Stomach NeoplasmsFirst studyNCT05702229 · 163 planned · United States, China, Japan and more
  2. Feb 23, 2023AstraZeneca licensed it from KYM Biosciences (Keymed and Lepu)LicenseWorldwide rights · announced · AstraZeneca
  3. Nov 21, 2023Phase 2 study in Stomach NeoplasmsNCT06219941 · 226 planned · United States, Australia, Canada and more
  4. Feb 28, 2024Phase 3 study in Stomach NeoplasmsNCT06346392 · 594 enrolled · United States, Brazil, Canada and more
  5. Aug 11, 2024Named sonesitatug vedotinINNProposed as its International Nonproprietary Name in WHO's List 131 · before, AZD0901, CMG901
  6. Jun 24, 2025Phase 2 study in Stomach NeoplasmsNCT07069712 · 100 planned · United States, Canada, China and more
  7. Aug 20, 2025Phase 2 study in Stomach NeoplasmsNCT07143604 · 33 enrolled · Russia
  8. Jan 16, 2026Phase 3 study in Stomach NeoplasmsNCT07431281 · 2,130 planned · United States, Australia, Austria and more

Ahead

  1. Nov 17, 2026Primary completion: phase 2 study in Stomach NeoplasmsNCT06219941
  2. Nov 9, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT07069712
  3. Nov 30, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT05702229
  4. Aug 16, 2029Primary completion: phase 3 study in Stomach NeoplasmsNCT07431281

TargetBeta

“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), w…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of sonesitatug, a monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
givastomigrulei-mab-biopharma-us-limitedphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 6 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07431281Stomach Neoplasms · United States, Australia, Austria and more3RecruitingAug 16, 20292,130
NCT07143604Stomach Neoplasms · Russia2Active, not recruitingAug 14, 202633
NCT07069712Stomach Neoplasms · United States, Canada, China and more2RecruitingNov 9, 2027100
NCT06346392Stomach Neoplasms · United States, Brazil, Canada and more3Active, not recruitingMay 31, 2026594
NCT06219941Stomach Neoplasms · United States, Australia, Canada and more2RecruitingNov 17, 2026226
NCT05702229Stomach Neoplasms · United States, China, Japan and more2RecruitingNov 30, 2027163

How it is read

Names in the registry

  • “AZD0901”, 5 entries
  • “Sonesitatug Vedotin”, 1 entry
  • “Sonesitatug vedotin”, 1 entry
  • “CMG901”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.